Management of Congenital Purpura Fulminans

Acute Management

Protein C replacement therapy is recommended as the primary intervention for skin lesions in congenital purpura fulminans due to homozygous protein C deficiency, offering superior long-term effectiveness compared to anticoagulation alone 1, 2, 3
Protein C replacement can be administered in the form of protein C concentrate or fresh-frozen plasma for management of acute exacerbations 4
When protein C replacement cannot be fully implemented due to cost constraints, a combination of anticoagulation plus protein C replacement is recommended rather than anticoagulation alone, to reduce the required intensity of anticoagulation and consequently reduce bleeding risk 1, 2, 3, 5

For long-term management, three main options exist: continued protein C replacement therapy, combined protein C replacement with anticoagulation, and liver transplantation, with liver transplantation being curative but carrying significant risks 1, 2, 3
Liver transplantation should be considered early, before progressive organ damage has occurred, particularly as the child grows and protein C replacement becomes increasingly expensive and difficult to maintain 1, 2, 3, 5

Protein C is expensive, and cost may be prohibitive in many healthcare settings, with the financial burden increasing as children grow due to weight-based dosing 1, 2, 3, 5
Long-term anticoagulation at high intensity carries significant bleeding risks, and vitamin K antagonists may paradoxically worsen skin necrosis during initiation due to rapid depletion of protein C 1, 2, 3, 6
If warfarin must be used, it should be started at a low dose under the coverage of therapeutic doses of parenteral anticoagulants, with gradual dose increases over 1 or more weeks 6

Protein C deficiency is a significant independent risk factor for venous thromboembolism with an odds ratio of 11.1 for cerebral venous thrombosis, according to the American Heart Association 7
Homozygous protein C deficiency causes congenital purpura fulminans, a life-threatening condition with historical mortality rates of 5% and pulmonary embolism rates of 38% when treated with anticoagulation alone, as reported by the American Society of Hematology 8, 9, 10

For acute episodes of congenital purpura fulminans, combination therapy with protein C replacement plus anticoagulation is superior to anticoagulation alone, as recommended by the International Society on Thrombosis and Haemostasis 10
Protein C replacement therapy is the preferred long-term treatment for homozygous protein C deficiency, offering superior effectiveness without the bleeding risks of high-intensity anticoagulation, according to the National Hemophilia Foundation 10

Targeted testing for protein C deficiency is recommended only when results will influence treatment decisions, particularly in patients with VTE and other risk factors, as suggested by the College of American Pathologists 11, 12
Testing is most appropriate when evaluating thrombophilia in patients with recurrent VTE or family history of thrombosis, according to the American College of Chest Physicians 7, 13